EGFR and non-small cell lung carcinoma: Concurrent HER2 amplification has been reported in 3–5% of patients with EGFR-mutant NSCLC, which was an independent predictor of shorter time to progression (HR=2.4, P=0.015) on EGFR TKI treatment.